Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ...
Cerebellar ataxia is a neurological disorder of the cerebellum. This important area at the back of the brain acts as a ...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
In such cases, an inability to balance is a symptom known as ataxia. But ataxia can also be its own condition or disease. As a stand-alone condition, "ataxia is a degenerative disease of the ...
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...
Fast-track status will allow Solid Biosciences to have more frequent meetings with the FDA throughout the treatment-development process and, potentially, get the product to patients faster than would ...
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Nomlabofusp For The Treatment Of Patients With Friedreich's Ataxia As I stated above, the company released positive initial data from the long-term open-label extension [OLE] study, using ...
The ataxia patient's MRI shows cerebellar atrophy and cervical spinal cord thinning. Repeat MRIs showed the atrophy slowly progressed over time. Advanced Search ...
Lions postgame injury report after season-ending loss to Commanders, with updates on Amik Robertson, Penei Sewell and more ...
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE ...